Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06861608 · ClinicalTrials.gov registry record · NA

A Single-session Intervention Adaptation of the Habit Framework for the Prevention of Eating Disorders

A NA study of Eating Disorder Not Otherwise Specified, sponsored by Virginia Commonwealth University.

Recruiting
Registry status
NA
Development phase
160
Enrollment target
1
Study location

NCT06861608: Recruiting NA study of Eating Disorder Not Otherwise Specified, sponsored by Virginia Commonwealth University.

NCT06861608 is a NA study of Eating Disorder Not Otherwise Specified that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 160 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06861608, a NA study of Eating Disorder Not Otherwise Specified, is actively recruiting participants, sponsored by Virginia Commonwealth University.

RECRUITING
Registry status
NA
Development phase
160 participants
Enrollment target
1
Study location

Study Summary

The purpose of this proposal is to launch the first trial of a single-session intervention (SSI) specifically for the prevention of eating disorders (EDs).

Primary Outcome

This 26-item measure will be used to assess eating disorder, including bingeing, purging, and exercise behaviors. According to this methodology, individuals who score 20 or more on the test should be interviewed by a qualified professional to determine if they meet the diagnostic criteria for an eating disorder. If you have a low score on the EAT-26 (below 20), you still could have a serious eating problem, so do not let the results deter you from seeking help. For example, some individuals with

Interventions

  • BEHAVIORAL Screening Questionnaire
  • BEHAVIORAL Pre-Intervention Questionnaires (~10 minutes)
  • BEHAVIORAL SSI (Single-session intervention (~30 minutes) Active arm
  • BEHAVIORAL SSI (Single-session intervention (~30 minutes) control arm
  • BEHAVIORAL End-of-Intervention Questionnaires (~5 minutes)

Study Locations (1)

Virginia

  • Virginia Commonwealth University - Richmond

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2025-01-15
Est. Completion 2026-07-15
Phase NA
Virginia Commonwealth University

558 total trials

What NCT06861608 shows while recruiting

NCT06861608 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Eating Disorder Not Otherwise Specified appearing as the primary indexed condition, and to 5 interventions - of which Screening Questionnaire is the first listed.

NCT06861608 reports a single indexed study location in Virginia.

Frequently Asked Questions

What is clinical trial NCT06861608 about?

NCT06861608 is a clinical study titled "A Single-session Intervention Adaptation of the Habit Framework for the Prevention of Eating Disorders". The purpose of this proposal is to launch the first trial of a single-session intervention (SSI) specifically for the prevention of eating disorders (EDs).

What is the current status of trial NCT06861608?

This trial is currently recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2025-01-15. Estimated completion is 2026-07-15.

What conditions does trial NCT06861608 study?

This clinical trial studies the following conditions: Eating Disorder Not Otherwise Specified.

What interventions are being tested in trial NCT06861608?

The interventions under investigation include: Screening Questionnaire (BEHAVIORAL), Pre-Intervention Questionnaires (~10 minutes) (BEHAVIORAL), SSI (Single-session intervention (~30 minutes) Active arm (BEHAVIORAL), SSI (Single-session intervention (~30 minutes) control arm (BEHAVIORAL), End-of-Intervention Questionnaires (~5 minutes) (BEHAVIORAL).

Who is sponsoring clinical trial NCT06861608?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06861608 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Eating Disorder Not Otherwise Specified

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06861608's enrollment target sits among peer trials

160 628th of 2000 higher than 1,347 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00501826 · 160 participants · Phase 2

    Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • NCT00932139 · 160 participants · NA

    Effect of Electro-Acupuncture on Blood Pressure

  • NCT00992901 · 160 participants · Early Phase 1

    Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

  • NCT01515527 · 160 participants · Phase 2

    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06861608, the US trial registry maintained by the National Library of Medicine. NCT06861608 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.